Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Total Current Liabilities: 2009-2024

Historic Total Current Liabilities for Gyre Therapeutics (GYRE) over the last 15 years, with Dec 2024 value amounting to $19.5 million.

  • Gyre Therapeutics' Total Current Liabilities rose 8.13% to $15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.9 million, marking a year-over-year increase of 8.13%. This contributed to the annual value of $19.5 million for FY2024, which is 2.65% down from last year.
  • Latest data reveals that Gyre Therapeutics reported Total Current Liabilities of $19.5 million as of FY2024, which was down 2.65% from $20.0 million recorded in FY2023.
  • Gyre Therapeutics' Total Current Liabilities' 5-year high stood at $20.0 million during FY2023, with a 5-year trough of $12.2 million in FY2022.
  • Over the past 3 years, Gyre Therapeutics' median Total Current Liabilities value was $19.5 million (recorded in 2024), while the average stood at $17.3 million.
  • Per our database at Business Quant, Gyre Therapeutics' Total Current Liabilities decreased by 20.40% in 2021 and then soared by 63.76% in 2023.
  • Over the past 5 years, Gyre Therapeutics' Total Current Liabilities (Yearly) stood at $17.8 million in 2020, then fell by 20.40% to $14.2 million in 2021, then decreased by 13.58% to $12.2 million in 2022, then soared by 63.76% to $20.0 million in 2023, then declined by 2.65% to $19.5 million in 2024.